Cyclerion Therapeutics, Inc. (KRSA) vs Novavax, Inc. (NVAX)
Cyclerion Therapeutics, Inc. and Novavax, Inc. are both Biotechnology companies. Cyclerion Therapeutics, Inc. and Novavax, Inc. are of similar size ($1.8B and $1.7B). Cyclerion Therapeutics, Inc. grew revenue faster over the last twelve months: 30.8% against −61.6%. Cyclerion Therapeutics, Inc. has the higher net margin (0.00% vs −59.9%) and the lower return on invested capital (−115.4% vs 0.00%). Across the 17 metrics below, Novavax, Inc. leads on 12 and Cyclerion Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | KRSA | NVAX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 78.60% | 65.16% |
| Operating margin | 0.00% | (56.58%) | 0.00% |
| Net margin | 0.00% | (59.87%) | 0.00% |
| Free cash flow margin | 0.00% | (10.20%) | 0.00% |
| Return on equity | (98.22%) | 323.66% | (57.72%) |
| Return on assets | (82.29%) | (21.62%) | (49.22%) |
| Return on invested capital | (115.40%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack